Skip to main content

Advertisement

Table 2 Key characteristics of participants at baseline in three trials that contributed individual participant data

From: Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials

Characteristic Aspirin group (N = 1188) Placebo group (N = 1118)
Age (years) 60.1 (8.9) 60.1 (8.6)
Male sex 455 (38.3) 433 (38.7)
Body mass index (kg/m2) 28.8 (5.7) 29.1 (6.0)
Systolic blood pressure (mmHg) 134.8 (14.4) 134.7 (13.8)
Total cholesterol (mmol/l)* 5.66 (1.20) 5.41 (1.16)
Smoking status
 Other 1015 (85.5) 966 (86.5)
 Current 172 (14.5) 151 (13.5)
History of hypertension
 No 469 (39.5) 453 (40.7)
 Yes 718 (60.5) 661 (59.3)
Baseline treatment for hypertension*
 No 489 (61.4) 455 (61.6)
 Yes 307 (38.6) 284 (38.4)
Family history of MI*
 No 666 (84.0) 623 (84.2)
 Yes 127 (16.0) 117 (15.8)
History of RA
 No 898 (98.4) 842 (97.9)
 Yes 15 (1.6) 18 (2.1)
  1. * Data contributed by two trials; values are mean (SD), median (IQR), or n (%); MI, myocardial infarction; rheumatoid arthritis